Skip to main content

Table 2 Adjusted risk of malignancy associated with antidiabetic medications, use vs. non-use

From: Risk factors for cancer development in type 2 diabetes: A retrospective case-control study

Antidiabetic medication ORa
(95 % CI)
P value ORb
(95 % CI)
P value ORc
(95 % CI)
P value
Metformin 0.294
(0.182–0.478)
<0.001 0.318
(0.193–0.523)
<0.001 0.310
(0.183–0.525)
<0.001
Sulfonylurea 0.735
(0.493–1.094)
0.129 0.859
(0.547–1.349)
0.508 0.906
(0.563–1.456)
0.683
Acarbose 1.333
(0.640–2.776)
0.443 1.372
(0.635–2.967)
0.421 1.245
(0.564–2.747)
0.587
DPP-4 inhibitors 1.954
(0.698–5.468)
0.202 2.809
(0.947–8.331)
0.063 3.468
(1.082–11.112)
0.036
Insulin 1.964
(1.227–3.144)
0.005 1.509
(0.879–2.588)
0.135 1.735
(0.986–3.053)
0.056
  1. a adjusted for BMI, diabetes duration and metabolic control
  2. b adjusted for BMI, diabetes duration, metabolic control and antidiabetic medications use
  3. c adjusted for BMI, diabetes duration, metabolic control, antidiabetic medications use, smoking history, place of residence, presence of comorbidities and aspirin use
  4. Data presented in bold are statistically significant